NCCN Guidelines® Insights - T-Cell Lymphomas, Version 2.2018
Natural killer (NK)/T-cell lymphomas are a rare and distinct subtype of non-Hodgkin’s lymphomas. NK/T-cell lymphomas are predominantly extranodal and most of these are nasal type, often localized to the upper aerodigestive tract.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Monograph/Journal Supplement
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN 2018 Nursing Program Webinar Series - Implementing a CAR T-Cell Therapy Program
Recent advances in immunotherapies are changing the standard of care for patients with cancer.
Category
  • Acute Lymphoblastic Leukemia
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
NCCN Task Force Report: Chimeric Antigen Receptor T-Cell Therapy
Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options.
Category
  • Acute Lymphoblastic Leukemia
  • Non-Hodgkin's Lymphoma
Format
  • Monograph/Journal Supplement
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Keynote Session: CAR T-cell Therapy - Focus on Lymphomas
Chimeric antigen receptor (CAR) T-cell therapy is a new and rapidly evolving immunotherapy emerging as a novel treatment option for relapsed or refractory lymphomas.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Keynote Session: CAR T-cell Therapy - Historical Perspectives and Major Milestones
Chimeric antigen receptor (CAR) T-cell therapy is an immune-based therapy used in cancer treatment that has demonstrated efficacy in the management of many hematologic malignancies, suggesting significant impact on oncology practice.
Category
  • Acute Lymphoblastic Leukemia
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Optimizing the Care of Patients Receiving CAR T-Cell Therapy
Patients with relapsed or refractory hematologic disorders like acute lymphoblastic leukemia and diffuse large B-cell lymphoma have poor outcomes and require novel effective therapies.
Category
  • Acute Lymphoblastic Leukemia
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Patient Case Studies and Panel Discussion: Lymphoma
Although advances in treatment options for patients with hematologic malignancies are encouraging, the rapidly changing scientific and clinical environment represents a daunting challenge for practitioners.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
CAR T-Cell Therapy: Recent Advances and Future Considerations
Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options.
Category
  • Acute Lymphoblastic Leukemia
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Optimizing Small Molecule Inhibitor Therapy for Relapsed/Refractory B-cell Lymphomas
The goal of this program is to ensure that members of the interprofessional oncology care team, including physicians, nurses, pharmacists and other relevant health care professionals, have the knowledge and skills necessary to apply the standards of care to their practice and health care setting
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation